Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.~* Patients must have experienced an exacerbation of their illness within the previous 2 weeks.~* Patients in whom a switch to another antipsychotic medication is acutely indicated.~Exclusion Criteria:~* Patients who are deemed nonresponsive to risperidone or olanzapine.~* Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.~* Patients having received olanzapine or risperidone in the past 30 days.~* Treatment with clozapine within 1 year prior to Visit 1.~* Diagnosis of substance-induced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).~* A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Olanzapine for Not Early Onset response (NEO) patients
- 2 (Type: ACTIVE_COMPARATOR): Risperidone for Not Early Onset response (NEO) patients
- 3 (Type: ACTIVE_COMPARATOR): Risperidone for Early Onset response (EO) patients

Based on this trial design, predict the completion outcome and termination type (if applicable).